Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGeisinger Health PlanGeisinger Health Plan COPD Prior Auth Update | Ope…
    Ask Trek AI about this page
    CurrentGeisinger Health PlanPolicy N/A

    COPD Agents Prior Authorization (PDE inhibitors and other COPD agents)

    Customize your policy alerts

    Sign up for all Geisinger Health Plan policy alerts

    Know when Geisinger Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization form and requirements for COPD pharmacologic agents (including PDE inhibitors such as roflumilast and ensifentrine) for Geisinger Health Plan members; applies to prescribers requesting new or renewal coverage. Providers must complete the form and submit required clinical documentation.

    Policy Summary
    PayerGeisinger Health Plan
    PolicyCOPD Agents Prior Authorization (PDE inhibitors and other COPD agents)
    Policy CodePolicy N/A
    Change TypeAdministrative (form effective date)
    Effective DateJul 6, 2026
    Next Review DateN/A
    Key ActionSubmit the completed COPD Agents Prior Authorization Form with required clinical documentation via PromptPA or fax for new and renewal requests.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    7/6/2026form effective date
    1pages
    855-552-6028pharmacy customer service
    570-271-5610prior auth fax
    Policy Summary
    PayerGeisinger Health Plan
    PolicyCOPD Agents Prior Authorization (PDE inhibitors and other COPD agents)
    Policy CodePolicy N/A
    Change TypeAdministrative (form effective date)
    Effective DateJul 6, 2026
    Next Review DateN/A
    Key ActionSubmit the completed COPD Agents Prior Authorization Form with required clinical documentation via PromptPA or fax for new and renewal requests.
    SourceLink
    On This Page
    Coverage Criteria for COPD AgentsProvider Requirements and Submission InstructionsBackground and ScopeKey Definitions and Thresholds

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria for COPD Agents

    Initial Therapy

    Covered when ALL of the following are met (initial requests):

    PDE inhibitor specific criteria: For DALIRESP (roflumilast): member has COPD that is severe per current GOLD guidelines based on history, exam, and lung function; has chronic bronchitis with cough and sputum production ≥3 months per year in 2 consecutive years; does not have moderate or severe liver impairment (Child-Pugh B or C). For OHTUVAYRE (ensifentrine): member has COPD that is moderate to severe per current GOLD guidelines based on history, exam, and lung function; has a Modified Medical Research Council (mMRC) Dyspnea Scale score ≥2.

    Prescriber must document findings on the prior authorization form; liver impairment is a contraindication for roflumilast.

    Common PDE inhibitor prerequisites: Other causes of chronic airflow limitation have been excluded (e.g., asthma, bronchiectasis, heart failure, tuberculosis); member has tried and failed or has a contraindication/intolerance to first-line therapies per current GOLD guidelines (inhaled LABA, inhaled LAMA, and inhaled corticosteroid unless eosinophils <100 cells/µL; submit eosinophil lab results when applicable).

    Document trials, failures, or contraindications on the form; refer to preferred drug list for other COPD agents.

    Mental health evaluation: Member does not have suicidal ideations. For beneficiaries with a history of suicide attempt(s), bipolar disorder, major depressive disorder, schizophrenia, substance use disorder(s), anxiety disorder(s), borderline or antisocial personality disorder: was evaluated and treated by a psychiatrist. For beneficiaries without such history: had a mental health evaluation by the prescriber and is a candidate for treatment.

    Applies to all PDE inhibitors due to psychiatric risk warnings; document evaluation and prescriber's determination of candidacy.

    Continuation/Renewal Therapy

    Covered on renewal when ALL of the following are met:

    Daliresp renewal: Frequency of COPD exacerbations has decreased since starting Daliresp; member does not have moderate or severe liver impairment (Child-Pugh B or C).

    Requires documentation of change in exacerbation frequency and current liver status in recent chart notes.

    Ohtuvayre renewal: Member experienced a positive clinical response to Ohtuvayre demonstrated by increased pulmonary function, decreased dyspnea severity, decreased use of rescue medications, or decreased symptom severity; member does not have suicidal ideations and was evaluated for new or worsening anxiety or depression; is a candidate for continued treatment.

    Positive response and mental health assessment must be documented in chart notes.

    Other COPD agents renewal: Submit completed beneficiary, prescriber, and drug fields and provide recent chart notes demonstrating ongoing benefit or clinical need for continued therapy.

    Follow form instructions for renewal requests and include supporting documentation when submitting to PromptPA or fax.

    Roflumilast (Daliresp) is contraindicated in beneficiaries with moderate or severe liver impairment (Child-Pugh B or C). This contraindication must be documented in the chart for both initial and renewal requests; lack of documentation may result in denial.

    Requests for phosphodiesterase (PDE) inhibitors without required clinical documentation are not acceptable. Providers must document COPD severity per current GOLD criteria, required disease-specific findings (for example, chronic bronchitis criteria or an mMRC score ≥2 where applicable), prior trials and failures or documented contraindications/intolerances to first-line therapies (LABA, LAMA, and inhaled corticosteroid when indicated), and mental health evaluation or specialist treatment when indicated (history of serious mental health or substance use disorders). Renewal requests must also include objective evidence of benefit (e.g., decreased exacerbation frequency for roflumilast or improved pulmonary function/symptoms for ensifentrine).

    Provider Requirements and Submission Instructions

    Prior Authorization

    Prior authorization required

    Prior authorization is required for COPD agents. Providers must submit the completed COPD Agents Prior Authorization Form and required clinical documentation for both new and renewal requests via PromptPA or fax.

    • Submit new and renewal requests using the COPD Agents Prior Authorization Form.
    • Acceptable submission routes: PromptPA (https://ghp.promptpa.com) or fax to 570-271-5610.
    Step Therapy

    Step / therapeutic trial requirements

    Document a trial and failure, or a documented contraindication or intolerance, to preferred first-line therapies before requesting PDE inhibitors or other non-preferred COPD agents.

    • For PDE inhibitors and other non-preferred COPD agents, document trials of LABA and LAMA and inhaled corticosteroid (unless eosinophils <100 cells/µL with lab documentation).
    • Refer to the preferred drug list for preferred vs non-preferred COPD agents (papdl.com).
    Documentation Required

    Required submission materials

    Include a completed prior authorization form with beneficiary and prescriber information, drug requested (strength, directions, quantity, duration), diagnosis with ICD-10 code, and recent chart notes demonstrating required clinical criteria.

    • Ensure drug fields (strength, directions, quantity, duration) are completed.
    • Include diagnosis and required ICD-10 code and supporting clinical documentation (e.g., lung function, mMRC score, exacerbation history).
    • Submit completed form and supporting documentation via PromptPA or fax to 570-271-5610.
    Denial Risk

    Documentation deficiencies may cause denial or return

    Requests missing required clinical documentation may be denied or returned. Missing documentation can include lack of disease severity evidence, absence of prior trials/failures or contraindication documentation, missing mental health evaluation when indicated, or no evidence of benefit on renewal.

    • Failure to document contraindication status (e.g., liver impairment for roflumilast) can lead to denial.
    • Renewal requests must document clinical benefit (e.g., decreased exacerbations for roflumilast or objective improvement with ensifentrine).

    Background and Scope

    This prior authorization form covers the pharmacologic management of COPD, including phosphodiesterase (PDE) inhibitors such as roflumilast (Daliresp) and ensifentrine (Ohtuvayre). It requires documentation of disease severity per current GOLD guidelines, agent-specific criteria (for example, chronic bronchitis and absence of moderate-to-severe liver impairment for roflumilast; mMRC score ≥2 for ensifentrine), exclusion of other causes of chronic airflow limitation, and evidence of trials/failures or contraindications to first-line inhaled therapies. The form applies to both new and renewal requests and must be submitted with supporting clinical records via PromptPA or fax.

    Key Definitions and Thresholds

    Chronic bronchitis
    DefinitionCough and sputum production for at least 3 months per year in 2 consecutive years.
    Clinical contextUsed to identify COPD patients with chronic bronchitis phenotype for Daliresp (roflumilast) consideration.
    Documentation requiredPrescriber must document duration and pattern of cough and sputum production in chart notes or the prior authorization form.
    mMRC Dyspnea Scale threshold
    ThresholdScore of ≥2 on the Modified Medical Research Council (mMRC) Dyspnea Scale is required for OHTUVAYRE (ensifentrine).
    PurposeDefines symptom severity for ensifentrine eligibility (moderate to severe COPD per GOLD).
    DocumentationmMRC score must be recorded in clinical notes or on the prior authorization form to support initiation.
    Liver impairment contraindication
    ContraindicationModerate or severe liver impairment (Child-Pugh B or C) is a contraindication to roflumilast (Daliresp).
    AssessmentAssess liver function and document Child-Pugh classification before prescribing roflumilast.
    Renewal considerationRenewal criteria require continued absence of moderate or severe liver impairment; document ongoing liver status in renewal notes.